Literature DB >> 8305285

Use of isotopically chiral [4'-13C]penciclovir and 13C NMR to determine the specificity and absolute configuration of penciclovir phosphate esters formed in HSV-1 and HSV-2 infected cells and by HSV-1-encoded thymidine kinase.

R A Vere Hodge1, S J Darlison, D L Earnshaw, S A Readshaw.   

Abstract

Penciclovir is a potent antiherpesvirus agent which is highly selective due to its phosphorylation only in virus infected cells. Phosphorylation of one of the hydroxymethyl groups of penciclovir (PCV) creates a chiral centre leading to the possible formation of (R)- and (S)-enantiomers. The absolute configuration and stereospecificity of the PCV-phosphates produced in cells infected with herpes simplex viruses types 1 and 2 (HSV-1 and HSV-2), as well as by HSV-1-encoded thymidine kinase, were determined using isotopically chiral [4'-13C]PCV precursors and 13C NMR spectroscopy of the isolated metabolites. The absolute configuration of penciclovir-triphosphate (PCV-TP) produced in HSV-1 infected cells was shown to be S with an enantiomeric purity of greater than 95%. However, in contrast fo HSV-1-infected cells in which none of the (R) enantiomer was detected, about 10% of (R)-PCV-TP was produced in HSV-2-infected cells. Phosphorylation of PCV by HSV-1-encoded thymidine kinase was found to give 75% (S)- and 25% (R)-PCV-monophosphate. The proportion of the (S)-isomer appears to be amplified in the subsequent phosphorylations leading to the triphosphate.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8305285     DOI: 10.1002/chir.530050804

Source DB:  PubMed          Journal:  Chirality        ISSN: 0899-0042            Impact factor:   2.437


  4 in total

1.  Famciclovir for the management of genital herpes simplex in patients with inadequate response to aciclovir or valaciclovir.

Authors:  Stephen L Sacks; Fred Y Aoki
Journal:  Clin Drug Investig       Date:  2005       Impact factor: 2.859

2.  Mode of action of (1'S,2'R)-9-[[1',2'-bis(hydroxymethyl) cycloprop-1'-yl]methyl]guanine (A-5021) against herpes simplex virus type 1 and type 2 and varicella-zoster virus.

Authors:  N Ono; S Iwayama; K Suzuki; T Sekiyama; H Nakazawa; T Tsuji; M Okunishi; T Daikoku; Y Nishiyama
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

Review 3.  Acyclic nucleosides as antiviral compounds.

Authors:  S Freeman; J M Gardiner
Journal:  Mol Biotechnol       Date:  1996-04       Impact factor: 2.695

Review 4.  New antiviral agents.

Authors:  Nahed Abdel-Haq; Pimpanada Chearskul; Hossam Al-Tatari; Basim Asmar
Journal:  Indian J Pediatr       Date:  2006-04       Impact factor: 5.319

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.